GlobalData

Japan will see the most impressive relative growth, with sales expanding from $47 million in 2014 to $268 million in 2024

The increase represents a tepid CAGR of 1.52 per cent across Argentina and the seven major markets of the US, France, Italy,…

The report also states that Roche’s Rituxan has emerged as the most clinically and commercially attractive therapy that is used in…

The global treatment market for melanoma will expand more than fourfold in value from $1.34 billion in 2013 to reach an estimated…

The company’s latest report states that this growth was marginally slower than during the previous five years

Across the eight major markets of the US, France, Germany, Italy, Spain, UK, Japan and Canada, growth will be driven primarily by…

It has been proposed that one should err on the side of short-term therapy for patients at high risk of bleeding